Table 4. PRP ordinal comparisons within groups and individuals under the prediction longer PRPs would be observed during the FI trials compared to baseline trials.

		Group	Bee 1	Bee 2	Bee 3	Bee 4	Bee 5	Bee 6	Bee 7	Bee 8	Bee 9	Bee 10
0-0-X	PCC	0.44	0.59	0.55	0.29	0.33	0.72	0.50	0.38	0.44	0.43	0.21
	c -value	1.00	0.01	0.01	1.00	1.00	1.00	0.03	1.00	1.00	1.00	1.00
0-15-X	PCC	0.56	0.71	0.75	0.52	0.74	0.64	0.32	0.60	0.38	0.38	0.62
	c -value	0.01	0.01	0.01	0.01	0.01	0.01	1.00	0.01	1.00	1.00	0.01
0-30-X	PCC	0.60	0.48	0.74	0.50	0.50	0.57	0.60	0.82	0.84	0.37	0.71
	c -value	0.01	0.99	0.01	0.52	0.57	0.01	0.01	0.01	0.01	1.00	0.01
0-60-X	PCC	0.52	0.49	0.37	0.34	0.57	0.68	0.48	0.41	0.57	0.11	0.52
	c -value	0.01	0.46	1.00	1.00	0.01	0.01	0.97	1.00	0.01	1.00	0.07
0-120-X	PCC	0.50	*	0.24	0.34	1.00	0.78	0.52	0.82	0.59	0.36	0.30
	c-value	0.02	*	1.00	1.00	0.01	0.01	0.04	0.13	0.01	1.00	1.00

PCC values and accompanying c-values are displayed for individuals and pooled groups. Ten of 40 subjects had larger PRPs during the FI trials compared to baseline for at least 70% of the observations (PCC values greater than 70%).

^*Subject did not make enough responses for PRP analysis.